Ascendis Pharma A/S
ASND
Rangering i aksjer
#1490
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aksjekurs
$233.77
Markedsverdi
$14.58B
Endring (1 dag)
1.66%
Endring (1 år)
13.92%
Land
DK
Handel Ascendis Pharma A/S (ASND)
Kategori
Healthcare
P/S-forhold for Ascendis Pharma A/S (ASND)
P/S-forhold per October 2026 TTM: 11.93
Ifølge Ascendis Pharma A/S sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 11.93. Ved slutten av 2023 hadde selskapet et P/S-forhold på 24.05.
P/S-historikk for Ascendis Pharma A/S fra 2011 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 11.93 | -43.64% |
| 2024 | 21.17 | -11.98% |
| 2023 | 24.05 | -80.76% |
| 2022 | 124.97 | -85.00% |
| 2021 | 833.09 | -16.14% |
| 2020 | 993.40 | 130.30% |
| 2019 | 431.35 | 103.35% |
| 2018 | 212.13 | -70.89% |
| 2017 | 728.64 | 557.34% |
| 2016 | 110.85 | 125.22% |
| 2015 | 49.22 | 161.17% |
| 2014 | 18.84 | 160.08% |
| 2013 | 7.25 | -26.75% |
| 2012 | 9.89 | 0.00% |
| 2011 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -16.00% |
US
|
|
| 40.55 | 239.89% |
US
|
|
| 3.96 | -66.80% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -14.96% |
NL
|
